Live Breaking News & Updates on Corbus Pharmaceuticals Trading
Stay updated with breaking news from Corbus pharmaceuticals trading. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com downgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a hold rating to a sell rating in a research report released on Saturday. Other research analysts have also recently issued reports about the company. Oppenheimer boosted their price target on Corbus Pharmaceuticals from $58.00 to $60.00 and gave the stock an outperform rating […] ....
Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […] ....
StockNews.com started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Trading Up 6.5 % NASDAQ:CRBP opened at $6.16 on Monday. The company has a market capitalization of $27.25 million, a P/E […] ....
StockNews.com initiated coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research note published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, Oppenheimer reissued an outperform rating and issued a $22.00 price objective on shares of Corbus Pharmaceuticals in a research note on Wednesday, August […] ....
StockNews.com assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. CRBP has been the topic of several other research reports. Oppenheimer raised Corbus Pharmaceuticals from a “market perform” rating to an […] ....